Metformin as a cardioprotective agent in doxorubicin treatment: A review paper

  • سال انتشار: 1398
  • محل انتشار: پانزدهمین همایش سراسری سم شناسی ایران
  • کد COI اختصاصی: TOXICOLOGY15_090
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 465
دانلود فایل این مقاله

نویسندگان

Amir Hossein Ajzashokouhi

School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Hasan Badie Bostan

Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran

A Wallace Hayes

University of South Florida, Tampa, FL USA, and Michigan State University, East Lansing, MI, USA

Gholamreza Karimi

School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran- Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran

چکیده

Introduction: doxorubicin (DOX) is an antineoplastic medication obtained from Streptomyces peucetius. It is used in treating different kinds of cancers such as leukemia, lymphoma, lung, and breast. The main side effect of DOX is cardiotoxicity. Metformin (MET) is an antihyperglycemic drug used for type 2 diabetes treatment. It is proposed that MET has a protective effect against DOX cardiotoxicity.Methods: We reviewed the following databases PubMed, Scopus, ScienceDirect, and Web of Science using the following search terms (keywords) doxorubicin, cardiotoxicity, metformin, adriamycin and heart failure over the years 1980 to February 2019. Only articles in English were reviewed and used in this peer-review.Results: our review demonstrated that MET has several possible mechanisms of action which can prevent or at least reduce DOX-cardiotoxicity including a decrease of free radical generation and oxidative stress, 5 adenosine monophosphate-activated protein kinase (AMPK) activation and ferritin heavy chain (FHC) expression in cardiomyocytes cells. The combination of MET and DOX has been shown to enhance the anti-cancer activity of DOX by a number of authors.Conclusion: oxidative stress is one of the most important mechanisms of DOX-induced heart damage. This drug also has been shown to change aerobic metabolism to anaerobic metabolism. MET can increase the cellular energy level by activation of AMPK, thus increasing the rate of cell survival. Iron hemostasis plays an important role in oxidative stress-induced by DOX in the heart. Increasing the cytosolic and mitochondrial free iron pools induced by DOX can be prevented or at least reduced by MET through FHC expression. DOX has been shown to liberate calcium from the sarcoplasmic reticulum and MET can reduce the [Ca2+]i and thereby, attenuated the DOX-cardiotoxicity. DOX can induce autophagy dysregulation which has been reported to be alleviated by the use of MET.

کلیدواژه ها

Doxorubicin, Metformin, Cardiotoxicity, Heart failure, Protective, Adriamycin

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.